Financial Instruments and Fair Value Measurements (Schedule of Reconciliation of Changes in Fair Value of Contingent Liabilities) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 29, 2019	Dec. 28, 2018
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent Consideration, Liability, Current	$ 52.5
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Contingent Consideration, Liability, Noncurrent	105.3
Level 3 | Recurring | Contingent Liabilities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	151.4
Accretion expense	0.9
Fair value adjustment	5.5
Ending balance	157.8
Questcor Pharmaceuticals, Inc. | Level 3 | Recurring
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value of contingent liability	77.1	$ 76.2
StrataGraft [Member] | Stratatech | Level 3 | Recurring
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value of contingent liability	57.5	53.7
MNK-6105 [Member] | Ocera [Member] | Level 3 | Recurring
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Contingent Consideration, Liability	23.2	$ 21.5
Maximum | Synacthen | Questcor Pharmaceuticals, Inc.
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Milestone Payment	$ 115.0